Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Shares Issued (2021 - 2025)

Barinthus Biotherapeutics' Shares Issued history spans 5 years, with the latest figure at $2000.0 for Q2 2025.

  • For Q2 2025, Shares Issued rose 100.4% year-over-year to $2000.0; the TTM value through Dec 2025 reached $2000.0, changed N/A, while the annual FY2025 figure was $2000.0, N/A changed from the prior year.
  • Shares Issued reached $2000.0 in Q2 2025 per BRNS's latest filing, up from -$1.3 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $102.8 million in Q3 2021 to a low of -$102.8 million in Q4 2021.
  • Average Shares Issued over 5 years is $49500.0, with a median of $243000.0 recorded in 2022.
  • Peak YoY movement for Shares Issued: skyrocketed 100.47% in 2022, then crashed 497.93% in 2023.
  • A 5-year view of Shares Issued shows it stood at -$102.8 million in 2021, then surged by 100.47% to $484000.0 in 2022, then plummeted by 497.93% to -$1.9 million in 2023, then skyrocketed by 31.15% to -$1.3 million in 2024, then soared by 100.15% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Shares Issued are $2000.0 (Q2 2025), -$1.3 million (Q4 2024), and $1.3 million (Q3 2024).